Rifaximin Use, Adherence and Persistence in Patients with Hepatic Encephalopathy: A Real-World Study in the South of Italy
Real-world data on the therapeutic management of hepatic encephalopathy (HE) patients are limited. The aim of this study was to evaluate the HE medications prescribed in an Italian cohort of HE patients post-discharge and to assess the real-world rifaximin adherence and persistence over 1 year. An observation retrospective study was conducted using data retrieved from outpatient pharmaceutical databases and hospital discharge records of the Campania region. For all subjects hospitalized for HE during 2019 (cohort 1), the HE medications prescribed within 60 days after discharge were evaluated. Adherence (proportion of days covered, PDC) and persistence were estimated for rifaximin 550 mg incident users over 1 year (cohort 2). Patients with PDC ≥80% were considered adherents. Persistence was defined as the period of time from the first rifaximin prescription to the date of discontinuation. Discontinuation was assessed using the permissible gap method. In cohort 1, 544 patients were identified; 58.5% received rifaximin while 15.6% only received non-absorbable disaccharides and 25.9% did not receive any HE medications. In cohort 2, 650 users were selected; only 54.5% were adherents and 35% were persistent users at 1 year. This real-world study highlights that quality improvement in therapeutic management is needed to potentially improve the outcomes of HE patients..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Journal of Clinical Medicine - 12(2023), 13, p 4515 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fulvio Pandico [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Adherence |
|---|
| doi: |
10.3390/jcm12134515 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ094002266 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ094002266 | ||
| 003 | DE-627 | ||
| 005 | 20240413024106.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240413s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/jcm12134515 |2 doi | |
| 035 | |a (DE-627)DOAJ094002266 | ||
| 035 | |a (DE-599)DOAJc6acecce3a284d57985a2dd04dd7ee2c | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a Fulvio Pandico |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rifaximin Use, Adherence and Persistence in Patients with Hepatic Encephalopathy: A Real-World Study in the South of Italy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Real-world data on the therapeutic management of hepatic encephalopathy (HE) patients are limited. The aim of this study was to evaluate the HE medications prescribed in an Italian cohort of HE patients post-discharge and to assess the real-world rifaximin adherence and persistence over 1 year. An observation retrospective study was conducted using data retrieved from outpatient pharmaceutical databases and hospital discharge records of the Campania region. For all subjects hospitalized for HE during 2019 (cohort 1), the HE medications prescribed within 60 days after discharge were evaluated. Adherence (proportion of days covered, PDC) and persistence were estimated for rifaximin 550 mg incident users over 1 year (cohort 2). Patients with PDC ≥80% were considered adherents. Persistence was defined as the period of time from the first rifaximin prescription to the date of discontinuation. Discontinuation was assessed using the permissible gap method. In cohort 1, 544 patients were identified; 58.5% received rifaximin while 15.6% only received non-absorbable disaccharides and 25.9% did not receive any HE medications. In cohort 2, 650 users were selected; only 54.5% were adherents and 35% were persistent users at 1 year. This real-world study highlights that quality improvement in therapeutic management is needed to potentially improve the outcomes of HE patients. | ||
| 650 | 4 | |a hepatic encephalopathy | |
| 650 | 4 | |a rifaximin | |
| 650 | 4 | |a adherence | |
| 650 | 4 | |a persistence | |
| 650 | 4 | |a drug utilization | |
| 650 | 4 | |a real-world data | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a Anna Citarella |e verfasserin |4 aut | |
| 700 | 0 | |a Simona Cammarota |e verfasserin |4 aut | |
| 700 | 0 | |a Francesca Futura Bernardi |e verfasserin |4 aut | |
| 700 | 0 | |a Ernesto Claar |e verfasserin |4 aut | |
| 700 | 0 | |a Carmine Coppola |e verfasserin |4 aut | |
| 700 | 0 | |a Marianna Cozzolino |e verfasserin |4 aut | |
| 700 | 0 | |a Federica De Rosa |e verfasserin |4 aut | |
| 700 | 0 | |a Massimo Di Gennaro |e verfasserin |4 aut | |
| 700 | 0 | |a Marianna Fogliasecca |e verfasserin |4 aut | |
| 700 | 0 | |a Roberta Giordana |e verfasserin |4 aut | |
| 700 | 0 | |a Daniela Pacella |e verfasserin |4 aut | |
| 700 | 0 | |a Alessandro Russo |e verfasserin |4 aut | |
| 700 | 0 | |a Vito Salerno |e verfasserin |4 aut | |
| 700 | 0 | |a Luca Scafa |e verfasserin |4 aut | |
| 700 | 0 | |a Ugo Trama |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Journal of Clinical Medicine |d MDPI AG, 2013 |g 12(2023), 13, p 4515 |w (DE-627)DOAJ000006793 |x 20770383 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g number:13, p 4515 |
| 856 | 4 | 0 | |u https://doi.org/10.3390/jcm12134515 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/c6acecce3a284d57985a2dd04dd7ee2c |z kostenfrei |
| 856 | 4 | 0 | |u https://www.mdpi.com/2077-0383/12/13/4515 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2077-0383 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2023 |e 13, p 4515 | ||